Share
array:23 [ "pii" => "S0300289624002151" "issn" => "03002896" "doi" => "10.1016/j.arbres.2024.05.033" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "3591" "copyright" => "SEPAR" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2024;60:634-42" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0300289624002187" "issn" => "03002896" "doi" => "10.1016/j.arbres.2024.06.001" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "3594" "copyright" => "SEPAR" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Bronconeumol. 2024;60:643-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:9 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>" "titulo" => "New Indicators of Exercise Capacity and Respiratory Function in COPD Patients: The Role of Gastrocnemius Muscle Oxygenation and Elastography Levels" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "643" "paginaFinal" => "645" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Buğra Kerget, İsmail Çınar, Büşra Nur Akdağ, Mustafa Yeşilyurt, Muhammed Furkan Barutçugil, Fatih Alper" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Buğra" "apellidos" => "Kerget" ] 1 => array:2 [ "nombre" => "İsmail" "apellidos" => "Çınar" ] 2 => array:2 [ "nombre" => "Büşra Nur" "apellidos" => "Akdağ" ] 3 => array:2 [ "nombre" => "Mustafa" "apellidos" => "Yeşilyurt" ] 4 => array:2 [ "nombre" => "Muhammed Furkan" "apellidos" => "Barutçugil" ] 5 => array:2 [ "nombre" => "Fatih" "apellidos" => "Alper" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289624002187?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000010/v1_202410020659/S0300289624002187/v1_202410020659/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0300289624001947" "issn" => "03002896" "doi" => "10.1016/j.arbres.2024.05.029" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "3587" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2024;60:627-33" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Effect of CPAP Treatment on Cardiovascular Outcomes" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "627" "paginaFinal" => "633" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0020" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 886 "Ancho" => 1422 "Tamanyo" => 150840 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jordi de Batlle, Esther Gracia-Lavedán, Joan Escarrabill, Anna García-Altés, Elisenda Martinez Carbonell, Mario Henríquez-Beltrán, Manuel Sánchez-de-la-Torre, Ferran Barbé" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Jordi" "apellidos" => "de Batlle" ] 1 => array:2 [ "nombre" => "Esther" "apellidos" => "Gracia-Lavedán" ] 2 => array:2 [ "nombre" => "Joan" "apellidos" => "Escarrabill" ] 3 => array:2 [ "nombre" => "Anna" "apellidos" => "García-Altés" ] 4 => array:2 [ "nombre" => "Elisenda" "apellidos" => "Martinez Carbonell" ] 5 => array:2 [ "nombre" => "Mario" "apellidos" => "Henríquez-Beltrán" ] 6 => array:2 [ "nombre" => "Manuel" "apellidos" => "Sánchez-de-la-Torre" ] 7 => array:2 [ "nombre" => "Ferran" "apellidos" => "Barbé" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0020"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289624001947?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000010/v1_202410020659/S0300289624001947/v1_202410020659/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Spirometric Transition of at Risk Individuals and Risks for Progression to Chronic Obstructive Pulmonary Disease in General Population" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "634" "paginaFinal" => "642" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Yong Suk Jo, Chin Kook Rhee, Sang Hyuk Kim, Hyun Lee, Joon Young Choi" "autores" => array:5 [ 0 => array:3 [ "nombre" => "Yong Suk" "apellidos" => "Jo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Chin Kook" "apellidos" => "Rhee" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Sang Hyuk" "apellidos" => "Kim" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Hyun" "apellidos" => "Lee" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:4 [ "nombre" => "Joon Young" "apellidos" => "Choi" "email" => array:1 [ 0 => "tawoe@naver.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju, Republic of Korea" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Republic of Korea" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0025" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 886 "Ancho" => 1560 "Tamanyo" => 123400 ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Introduction</span><p id="par0020" class="elsevierStylePara elsevierViewall">Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by persistent airflow limitation and chronic respiratory symptoms. As a chronic disease, COPD interventions aim to reduce the risk of acute exacerbation and relieve symptoms in overt, advanced disease. Cigarette smoke inhalation is the main risk factor for developing COPD; other factors include poor lung growth and subsequently low maximal forced expiratory volume in 1<span class="elsevierStyleHsp" style=""></span>s (FEV<span class="elsevierStyleInf">1</span>), biomass exposure, and air pollution, especially in those who are at risk. Several recent studies have focused on patients with early disease; those with symptoms or physiological or radiological abnormalities are more likely to progress to COPD. To aid early identification and preventive measures, the Global Initiative for COPD (GOLD) suggested several definitions of early COPD.<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">1,2</span></a> COPD is recognized as a condition that progresses from upstream to downstream, and attention has focused on elucidating prodromal conditions preceding disease progression.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Preserved ratio impaired spirometry (PRISm) is defined as a FEV<span class="elsevierStyleInf">1</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>80% of the predicted value without airflow limitation, i.e., with a normal FEV<span class="elsevierStyleInf">1</span>/forced vital capacity (FVC) ratio.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">3</span></a> This was previously defined as restrictive pulmonary function,<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">4,5</span></a> GOLD-unclassifiable,<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">6</span></a> or even nonspecific findings.<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">7,8</span></a> PRISm is associated with more severe respiratory symptoms<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">4,5,9</span></a> and a higher risk of all-cause and respiratory mortality.<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">9–13</span></a> It is regarded as a transitional state, either progressing to overt airflow obstruction (AFO) or reverting to normal spirometry in longitudinal studies<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">6,10</span></a> in a significant proportion of individuals.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">14</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Studies have found associations between respiratory symptoms, such as chronic mucus production,<a class="elsevierStyleCrossRefs" href="#bib0235"><span class="elsevierStyleSup">15–17</span></a> and abnormalities on chest images.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">18</span></a> The concept of pre-COPD encompasses not only symptoms but also structural abnormalities compatible with those found in COPD (e.g., emphysema). Formerly referred to as GOLD 0, the most recent GOLD document labeled these symptoms and abnormalities pre-COPD.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">2</span></a> Although it is associated with a higher risk of developing COPD, pre-COPD can transition to other airway disease statuses, including normal spirometry.<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">19,20</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">While these airway diseases are acknowledged as precursors to COPD, not all patients progress to COPD. Indeed, many patients transition to normal lung function, as alluded to above. We examined the outcomes of individuals at risk of developing COPD by analyzing data collected prospectively from the general population. This well-constructed longitudinal cohort enables us to identify lung function trends over time and factors related to the development of airflow limitation.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Study population and eligibility criteria</span><p id="par0040" class="elsevierStylePara elsevierViewall">We used data from a longitudinal, population-based observational cohort study (the rural Ansung and urban Ansan cohort) that was a part of the Korean Genome Epidemiology Study (KoGES). This project recruited individuals from the general population aged 40–69 years to assess the incidence and risk factors of various chronic disorders. The initial baseline survey ran from 2001 to 2002, and subjects were followed biannually until 2014. At each visit, data on lifestyle characteristics, medical history, subjective symptoms, and disease incidence were collected. Methodological information was published previously.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">21</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">We included only participants who underwent spirometry at the baseline survey and attended at least two follow-up visits. Moreover, the participants had to have completed a questionnaire on respiratory symptoms, and radiological data used to define pre-COPD had to be available.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Clinical variables</span><p id="par0050" class="elsevierStylePara elsevierViewall">At the baseline assessment, demographic and socioeconomic data were obtained, including age, sex, body mass index (BMI), smoking history and pack-years, biomass exposure, residence (urban vs. rural), education level, and income. Anthropometric parameters (height and weight) were measured. A systematic questionnaire was used to assess medical history at the baseline visit, including symptoms (chronic bronchitis symptom and modified Medical Research Council [mMRC] dyspnea score), quality of life (EQ-5D-5L), and comorbidities (hypertension, diabetes mellitus, coronary artery disease [CAD], congestive heart failure [CHF], dyslipidemia, kidney disease, cerebrovascular disease, arthritis, thyroid disease, and metabolic syndrome).</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Lung function measurements</span><p id="par0055" class="elsevierStylePara elsevierViewall">Pulmonary function tests were performed by a skilled technician using a standard spirometer (Vmax-2130; Sensor Medics, Yorba Linda, CA, USA). Calibration and quality control were performed regularly based on guidelines.<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">22</span></a> Pre-bronchodilator values of FEV<span class="elsevierStyleInf">1</span> and FVC (in liters and percentage of the predicted value, respectively), the FEV<span class="elsevierStyleInf">1</span>/FVC ratio, and forced expiratory flow between 25% and 75% of vital capacity (FEF25–75) were obtained.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Radiologic findings</span><p id="par0060" class="elsevierStylePara elsevierViewall">Radiologic findings from chest X-rays were collected from radiologists. Patients who were reported to have emphysema, interstitial lung abnormalities, hyperinflation, or bronchiectasis at least once were considered to possess these features.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Definition of airway disease</span><p id="par0065" class="elsevierStylePara elsevierViewall">Airway disease is classified into distinct respiratory disorders. COPD is defined by a pre-bronchodilator FEV<span class="elsevierStyleInf">1</span>/FVC ratio<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.7. PRISm is defined as a pre-bronchodilator FEV<span class="elsevierStyleInf">1</span>/FVC ratio<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>0.7 and a FEV<span class="elsevierStyleInf">1</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>80%. The preclinical stage, called pre-COPD, is characterized by respiratory symptoms and structural or functional abnormalities, without obvious airflow limitation at any age. Incorporating criteria for Pre-COPD were as follows: the absence of airflow limitation (FEV<span class="elsevierStyleInf">1</span>/FVC<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>0.7) and FEV<span class="elsevierStyleInf">1</span><span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>80%; abnormal imaging findings like bullae, emphysema, or hyperinflation suggestive of air trapping; or the presence of respiratory symptoms such as chronic bronchitis (defined as cough and phlegm occurring for >3 months per year for >2 years) or dyspnea.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Statistical analysis</span><p id="par0070" class="elsevierStylePara elsevierViewall">All statistical analyses were conducted using R software (ver. 4.3.1; R Development Core Team, Vienna, Austria). The results are expressed as the mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>standard deviation for continuous variables and as numbers (percentages) for categorical variables. Clinical parameters were compared among normal, pre-COPD, PRISm, and COPD patients using ANOVA for continuous variables and the <span class="elsevierStyleItalic">χ</span><span class="elsevierStyleSup">2</span> test for categorical variables. Linear mixed models were used to analyze group differences in annual rates of lung function decline over a 12-year period, as indicated by FEV<span class="elsevierStyleInf">1</span>, FVC, the FEV<span class="elsevierStyleInf">1</span>/FVC ratio, and FEF25–75; covariates included age, sex, BMI, smoking history, and baseline FEV<span class="elsevierStyleInf">1</span>. Changes in airway disease categories during follow-up are shown using Sankey diagrams.</p><p id="par0075" class="elsevierStylePara elsevierViewall">Survival analysis was performed to identify the time to first AFO, defined as an FEV<span class="elsevierStyleInf">1</span>/FVC ratio<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.7 in the normal, pre-COPD, and PRISm groups. Cox regression models were used to calculate hazard ratios (HRs) of pre-COPD and PRISm (compared to the normal group) for the time to first AFO. Model 1 was adjusted for age, sex, BMI, smoking history and FEV<span class="elsevierStyleInf">1</span>, and model 2 was further adjusted for comorbid cardiovascular disease (CVD; the presence of hypertension, CAD, or CHF).</p><p id="par0080" class="elsevierStylePara elsevierViewall">Multivariate logistic regression was performed to evaluate differences in the risk of future AFO among the normal, pre-COPD, and PRISm groups. We analyzed AFO according to its occurrence at least once during the 12-year study period and its occurrence at the last visit (year 12). The covariates included age, sex, BMI, and smoking history in model 1, with comorbid CVD added in model 2.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Results</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Baseline characteristics of the airway disease group</span><p id="par0085" class="elsevierStylePara elsevierViewall">From the entire KOGES cohort of 10,030 individuals, 4762 were included in the analysis; we excluded those for whom classification of airway disease, and transition thereof, would be challenging due to missing pulmonary function, imaging, and respiratory symptom data. There were 66, 866, 289, and 3541 individuals in the PRISm, pre-COPD, COPD, and normal groups, respectively (<a class="elsevierStyleCrossRef" href="#sec0110">Fig. S1</a>).</p><p id="par0090" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> summarizes the baseline characteristics of the four groups. The COPD group was the oldest, had the highest proportions of males (80.6%) and smokers, and had the lowest levels of education and income. Chronic bronchitis symptoms were most prevalent in the pre-COPD and COPD groups. While dyspnea was more common in the airway disease groups compared to the normal group, the severity of dyspnea did not differ significantly among the airway disease groups. Comorbid hypertension was prevalent in both the PRISm and COPD groups, while diabetes was more prevalent in the PRISm group. Baseline spirometry in the PRISm group revealed low values FEV<span class="elsevierStyleInf">1</span> and FVC values. Both the PRISm and COPD groups had low FEF25–75 values. Emphysema, interstitial lung abnormalities, hyperinflation, and bronchiectasis were more prevalent among the PRISm, pre-COPD, and COPD groups compared to normal group. The feature of hyperinflation was more common in the pre-COPD group compared to the PRISm group, while interstitial lung abnormalities were more frequent in the PRISm group than in the pre-COPD group.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Longitudinal changes of lung function parameters</span><p id="par0095" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#fig0010">Fig. 1</a> shows the longitudinal trends in pulmonary function indicators. For FEV<span class="elsevierStyleInf">1</span>, the baseline values were higher in the normal and pre-COPD groups compared to the COPD and PRISm groups. However, the rate of decline was more rapid in the pre-COPD group than in the normal group, and the rate was significantly lower in the PRISm group (−40.2, −42.6, and −12.6<span class="elsevierStyleHsp" style=""></span>mL/year in the normal, pre-COPD, and PRISm groups, respectively). The rate of FEV<span class="elsevierStyleInf">1</span> decline in the PRISm group was significantly slower compared to both the normal and COPD groups.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">The baseline FVC was lowest in the PRISm group. However, the rate of decline was more gradual in the PRISm group (−2.4<span class="elsevierStyleHsp" style=""></span>mL/year) than in the normal (−33.7<span class="elsevierStyleHsp" style=""></span>mL/year) and COPD (−49.9<span class="elsevierStyleHsp" style=""></span>mL/year) groups.</p><p id="par0105" class="elsevierStylePara elsevierViewall">The baseline FEV<span class="elsevierStyleInf">1</span>/FVC ratio exceeded 70% in all groups except the COPD group. However, the rate of decline was more rapid in the pre-COPD group than the normal group. Compared to the COPD group, the rate of decline was faster in the normal, pre-COPD, and PRISm groups.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The baseline FEF25–75 was lower in the PRISm and COPD groups compared to the normal and pre-COPD groups. The rate of decline was more gradual in the PRISm (−37.9<span class="elsevierStyleHsp" style=""></span>mL/year) and COPD (−35.9<span class="elsevierStyleHsp" style=""></span>mL/year) groups compared to the normal (−83.3<span class="elsevierStyleHsp" style=""></span>mL/year) and pre-COPD (−83.5<span class="elsevierStyleHsp" style=""></span>mL/year) groups.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Transitions of airway group categories</span><p id="par0115" class="elsevierStylePara elsevierViewall">The transitions in airway groups among the enrollment, first assessment, and second assessment timepoints are shown in <a class="elsevierStyleCrossRef" href="#fig0015">Fig. 2</a>. There was no loss to follow-up at both timepoints. Of the subjects with COPD or normal findings at enrollment, approximately 79% and 85%, respectively, showed no change in status at the second assessment. However, of those initially categorized as pre-COPD or PRISm, 65% and 53%%, respectively, transitioned to the normal group. Notably, there were higher rates of transition from PRISm to COPD (13.6%) or pre-COPD (9.1%) compared to the transition from pre-COPD to COPD (4.4%) or PRISm (0.7%). At subsequent assessments, the majority of subjects in the COPD and normal groups showed no change in status. However, among those classified as pre-COPD, approximately 66% transitioned to normal status, while 3.5% transitioned to COPD. In the PRISm group, 21.6% transitioned to normal status, while 16.2% transitioned to pre-COPD and 10.8% to COPD.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Differences in time to first AFO among the normal, pre-COPD, and PRISm groups</span><p id="par0120" class="elsevierStylePara elsevierViewall">Significant group differences were observed in time to first AFO, in the order of the PRISm, pre-COPD, and normal groups (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 3</a>). Univariate and multivariate Cox regression analyses were used to evaluate factors influencing the time to first AFO (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). In the univariate analyses, the pre-COPD and PRISm groups had HRs indicating elevated risk compared to the normal group. Old age, male sex, smoking status, low BMI, respiratory symptoms, comorbid CVD, and lower lung function parameters had significant associations with COPD progression. According to multivariate model 1, which considered age, sex, smoking status, BMI, smoking history, education level, income, and chronic bronchitis symptoms, both pre-COPD and PRISm significantly increased the risk of progression to COPD. However, in model 2, which also considered the presence of CVD, the impact of PRISm became non-significant.</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Differences in future risk of developing COPD among the groups</span><p id="par0125" class="elsevierStylePara elsevierViewall">To compare the risk of future AFO among groups, we used a multivariate logistic regression model (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). In the univariate analyses, the pre-COPD and PRISm groups had higher risks of developing AFO at least once during the 12-year follow-up (OR 1.89, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; OR 5.14, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001, respectively) and at the last visit (year 12) (OR 1.66, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; OR 4.31, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001, respectively). In the multivariate analysis adjusting for age, sex, BMI, and smoking history (model 1), both groups had significantly higher risks of future AFO at least during the 12-year follow-up (OR 1.80, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; OR 4.26, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001, respectively) and at the last visit (year 12) (OR 1.54, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; OR 3.21, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.004, respectively). After adding the presence of CVD as a covariate, the significance remained for the pre-COPD group developing AFO at the last visit (OR 1.63, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.019) but was lost for the PRISm group (OR 3.29, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.079).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Discussion</span><p id="par0130" class="elsevierStylePara elsevierViewall">This prospective cohort study sought to classify a substantial sample of the general population into airway groups based on lung function, respiratory symptoms, and radiological abnormalities. Group transitions were identified by analyzing follow-up data. Indicators of AFO, such a